EP Wealth Advisors LLC Has $860,000 Position in Boston Scientific Co. (NYSE:BSX)

EP Wealth Advisors LLC raised its stake in Boston Scientific Co. (NYSE:BSX) by 4.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,552 shares of the medical equipment provider’s stock after acquiring an additional 497 shares during the period. EP Wealth Advisors LLC’s holdings in Boston Scientific were worth $860,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Eagle Bay Advisors LLC boosted its position in shares of Boston Scientific by 542.1% during the 1st quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 309 shares in the last quarter. First Foundation Advisors acquired a new stake in shares of Boston Scientific in the 1st quarter valued at $25,000. RiverPark Advisors LLC bought a new position in shares of Boston Scientific in the 1st quarter valued at $30,000. Northwest Investment Counselors LLC bought a new stake in shares of Boston Scientific during the 1st quarter worth $31,000. Finally, Sachetta LLC purchased a new position in shares of Boston Scientific in the 4th quarter worth about $32,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Trading Up 0.9 %

Boston Scientific stock traded up $0.66 during mid-day trading on Friday, hitting $74.92. The company’s stock had a trading volume of 7,585,375 shares, compared to its average volume of 6,295,007. The business has a 50 day moving average price of $76.48 and a 200-day moving average price of $70.20. Boston Scientific Co. has a 12 month low of $48.35 and a 12 month high of $79.43. The stock has a market cap of $109.92 billion, a price-to-earnings ratio of 62.40, a price-to-earnings-growth ratio of 2.64 and a beta of 0.78. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.66 and a quick ratio of 1.14.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.04. The company had revenue of $4.12 billion during the quarter, compared to analysts’ expectations of $4.02 billion. Boston Scientific had a return on equity of 16.80% and a net margin of 12.00%. Boston Scientific’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.53 EPS. As a group, analysts forecast that Boston Scientific Co. will post 2.35 EPS for the current year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP John Bradley Sorenson sold 17,587 shares of the stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $71.50, for a total transaction of $1,257,470.50. Following the completion of the sale, the executive vice president now owns 50,638 shares of the company’s stock, valued at approximately $3,620,617. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Boston Scientific news, EVP John Bradley Sorenson sold 17,587 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $71.50, for a total transaction of $1,257,470.50. Following the completion of the transaction, the executive vice president now owns 50,638 shares of the company’s stock, valued at approximately $3,620,617. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 14,011 shares of the stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $75.34, for a total value of $1,055,588.74. Following the completion of the sale, the executive vice president now owns 20,197 shares of the company’s stock, valued at approximately $1,521,641.98. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 62,441 shares of company stock worth $4,624,453. Insiders own 0.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on BSX shares. Argus lifted their price objective on shares of Boston Scientific from $80.00 to $95.00 and gave the stock a “buy” rating in a research report on Tuesday, May 28th. StockNews.com raised Boston Scientific from a “hold” rating to a “buy” rating in a report on Wednesday. Evercore ISI boosted their target price on Boston Scientific from $78.00 to $81.00 and gave the company an “outperform” rating in a research note on Tuesday, July 2nd. UBS Group increased their price target on Boston Scientific from $74.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, April 25th. Finally, Truist Financial boosted their price objective on Boston Scientific from $86.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. Two analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $84.76.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.